THINQ PHARMA-CRO LTD

Overview

THINQ PHARMA-CRO LTD is an active pharmaceutical ingredient (API) supplier with 7 active FDA Type II Drug Master Files, covering CETIRIZINE HYDROCHLORIDE USP; CIPROFLOXACIN HYDROCHLORIDE USP; FEXOFENADINE HYDROCHLORIDE USP; MECLIZINE HYDROCHLORIDE USP; OXYBUTYNIN CHLORIDE USP; POTASSIUM CHLORIDE USP.

API / Drug Master Files

THINQ PHARMA-CRO LTD holds 7 active (7 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• SUCRALFATE USPActive2024-07-04
• POTASSIUM CHLORIDE USPActive2023-09-29
• FEXOFENADINE HYDROCHLORIDE USPActive2021-09-04
• OXYBUTYNIN CHLORIDE USPActive2020-06-26
• CIPROFLOXACIN HYDROCHLORIDE USPActive2016-06-27
• MECLIZINE HYDROCHLORIDE USPActive2015-03-31
• CETIRIZINE HYDROCHLORIDE USPActive2015-01-14

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to THINQ PHARMA-CRO LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.